Shukra (SHUKRAPHAR) | Stock Overview & Key Data
Shukra Performance Comparison
Stock Range
Today's Range
Low: ₹34.45
High: ₹34.45
on October 3, 2025
52 Week Range
Low: ₹5.75
High: ₹35.86
on November 21, 2024
on September 30, 2025
All-Time High: ₹35.86 on September 30, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR16.0B
EPS
0.13
P/E Ratio (TTM)
275.85
Forward P/E
N/A
P/B Ratio
25.61
PEG Ratio
3.37
Div. Yield
3.20%
ROE
15.24%
Beta
0.315
Debt to Equity
6.65
Financial Highlights
Profitability
Gross Margin
85.71%
Operating Margin
25.25%
Profit Margin
25.68%
Returns and Earnings
Return on Assets (TTM)
11.04%
Return on Equity (TTM)
15.24%
EBITDA
INR177.7M
Net Income (TTM)
INR101.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR0.90
Quarterly Revenue Growth (YoY)
66.90%
Quarterly Earnings Growth (YoY)
112.20%
Dividend Information
Last 12-Month Dividend
₹1.02
Current Dividend Yield
3.20%
3-Year Average Dividend Yield
3.91%
3-Year Average Annual Dividend
₹0.35
3-Year Total Dividends
₹1.05
Ex-Dividend Date
September 23, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Shukra SHUKRAPHAR | 16.02B Small-cap | -0.09% | 23.88% | 107.66% | 67.40% | 140.74% | 364.29% | 579.49% | 2,326.06% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Suven Life Sciences SUVEN | 48.20B Small-cap | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% | 46.77% | 186.97% | 307.88% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | 4.61% | 0.24% | 1.59% | 41.06% | 7.93% | -4.79% | -0.89% | -50.06% |
Ownership & Short Interest
Insider Ownership
89.33%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
110K
Average 90-Day Volume
341K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SHUKRAPHAR's 52-week high and low?
- In the last 52 weeks, Shukra reached a high of ₹35.86 (on September 30, 2025) and a low of ₹5.75 (on November 21, 2024).
- What is the market cap and P/E ratio for SHUKRAPHAR?
- Curious about Shukra's size and valuation? Its market capitalization stands at 16.02B. When it comes to valuation, the P/E ratio (trailing twelve months) is 275.85, and the forward P/E (looking ahead) is N/A.
- Does SHUKRAPHAR pay dividends? If so, what's the yield?
- Yes, Shukra is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.20%, and the company has paid an average of ₹0.35 per share annually over the past 3 years.
- Who are Shukra's main competitors or similar companies to consider before investing?
When looking at Shukra, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Suven Life Sciences
SUVEN48.20B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -4.79% -0.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Shukra Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Shukra's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 15.24%, the Debt to Equity ratio from the most recent quarter is 6.65, and its Gross Profit Margin stands at 85.71%.
- What is the recent revenue and earnings growth for SHUKRAPHAR?
- Looking at Shukra's growth, its revenue over the trailing twelve months (TTM) was INR394M. Compared to the same quarter last year (YoY), quarterly revenue grew by 66.90%, and quarterly earnings saw a YoY growth of 112.20%.
- How much of SHUKRAPHAR stock is held by insiders and institutions?
- Wondering who owns Shukra stock? Company insiders (like executives and directors) hold about 89.33% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.